Bio
John D. Cravero, Ph.D. is a licensed patent attorney of the life science group of Scully Scott Murphy and Presser, P.C. John counsels clients in the areas of life sciences, biotechnology, biologics, cell therapies, immunology, antibodies, pharmaceuticals, and related technologies. John has technical expertise in molecular and cellular biology, biochemistry, microbiology, animal models, and material science.
John drafts, prosecutes, and manages patent portfolios in the United States and globally. He regularly advises clients and prepares opinions for clients on invalidity, patentability, and non-infringement issues. He has also drafted briefs to the Patent Trials and Appeal Board in relation to inter partes examinations and interference proceedings.
John also has previous experience with intellectual property work outside of patent prosecution matters, including licensing, trademark prosecution, patent litigation, and has drafted briefs to both the Supreme Court of the United States of America and the United States Court of Appeals for the Federal Circuit.
Prior to entering private practice, John was a patent attorney for the United States Department of Energy. In this role, he wrote patentability opinions, drafted patent applications and prepared responses to Office Actions issued by the U.S. Patent and Trademark Office. John focused on patents in the biotechnology, chemical, material science, and renewable energy fields. He worked with inventors from national laboratories, universities, and small businesses to draft patents for technologies such as nanoparticle use in immunological detection, polymer compounds, surfactants, biofuels, photocathode electron sources, and ionic nanocrystalline materials.
John earned his Ph.D. in Molecular Medicine from Wake Forest University, where he researched cell signaling pathways of chondrocytes and discovered that the IGF-1 signaling inhibitor TRB3 is increased in osteoarthritis. As a post-doctoral researcher at Northwestern University, John studied pancreatic cancer where he used Kras mouse models to find that Cox-2 expression in EL-positive cells induces aberrant duct development.
Drawing on his research background and extensive experience as a patent attorney, John regularly writes on intellectual property issues relating to life sciences.
Practice Areas
Bio
John D. Cravero, Ph.D. is a licensed patent attorney of the life science group of Scully Scott Murphy and Presser, P.C. John counsels clients in the areas of life sciences, biotechnology, biologics, cell therapies, immunology, antibodies, pharmaceuticals, and related technologies. John has technical expertise in molecular and cellular biology, biochemistry, microbiology, animal models, and material science.
John drafts, prosecutes, and manages patent portfolios in the United States and globally. He regularly advises clients and prepares opinions for clients on invalidity, patentability, and non-infringement issues. He has also drafted briefs to the Patent Trials and Appeal Board in relation to inter partes examinations and interference proceedings.
John also has previous experience with intellectual property work outside of patent prosecution matters, including licensing, trademark prosecution, patent litigation, and has drafted briefs to both the Supreme Court of the United States of America and the United States Court of Appeals for the Federal Circuit.
Prior to entering private practice, John was a patent attorney for the United States Department of Energy. In this role, he wrote patentability opinions, drafted patent applications and prepared responses to Office Actions issued by the U.S. Patent and Trademark Office. John focused on patents in the biotechnology, chemical, material science, and renewable energy fields. He worked with inventors from national laboratories, universities, and small businesses to draft patents for technologies such as nanoparticle use in immunological detection, polymer compounds, surfactants, biofuels, photocathode electron sources, and ionic nanocrystalline materials.
John earned his Ph.D. in Molecular Medicine from Wake Forest University, where he researched cell signaling pathways of chondrocytes and discovered that the IGF-1 signaling inhibitor TRB3 is increased in osteoarthritis. As a post-doctoral researcher at Northwestern University, John studied pancreatic cancer where he used Kras mouse models to find that Cox-2 expression in EL-positive cells induces aberrant duct development.
Drawing on his research background and extensive experience as a patent attorney, John regularly writes on intellectual property issues relating to life sciences.
Education
- J.D., Chicago-Kent College of Law, Illinois Institute of Technology 2012
- Ph.D., Wake Forest University 2008
- B.A., Augustana College 2002